TapImmune Inc. (OTCMKTS:TPIV)’s chart performance is like a rollercoaster. The company stock constantly goes up and then comes flying down, although the daily percentile movements remain relatively small. The company has a market...
Yesterday the stock of TapImmune Inc. (OTCMKTS:TPIV) corrected by nearly 5% on an above-average volume of 614 thousand traded shares. At the end of the session the ticker was sitting at $0.61 per share. It...
At the end of Wednesday’s trading TapImmune Inc. (OTCMKTS:TPIV) issued a PR announcing that their cancer vaccine TPIV 200 in the treatment of ovarian cancer has received Orphan Drug Designation from the FDA. As...
For close to two and a half months the stock of TapImmune Inc (OTCMKTS:TPIV) fluctuated around the 60 cents per share mark. With the start of December, however, the positive momentum behind the ticker has...
TapImmune Inc.(OTCMKTS:TPIV) managed to climb all the way up to $0.725 on Monday, but unfortunately for its fervent supporters, its climb up the charts did not last, and it by the look of today’s...
TapImmune Inc. (OTCMKTS:TPIV) added another 8.39% to its market value yesterday, reaching a price of $0.64 once more. Should investors be worried? That was a trick question. TPIV is a development stage OTC Markets...
TapImmune Inc. (OTCMKTS:TPIV) added 10.18% to its market value yesterday – but will it keep its gains? There’s no simple answer to that question. As is usually the case with OTC Markets pharmaceutical companies,...
Yesterday, TapImmune Inc. (OTCMKTS:TPIV) lost all the gains it had managed to make in the previous session before it had even made it halfway through the day. What gives? Well, to answer that question,...
TapImmune Inc. (OTCMKTS:TPIV) had a positive session yesterday. It logged a dollar volume of about $190 thousand and after surging up nearly 30%, it closed the day with a price of $0.45 per share....
For three consecutive sessions TapImmune Inc. (OTCMKTS:TPIV) looked like it had finally found its place on the charts, but then yesterday saw it pushed 7.14% down, in spite of the fact that some information...